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Prostate cancer (PCa) is the most common cancer in men and the second most com-
mon cause of cancer-related death in men. In recent years, novel therapeutic options for
PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first
cell-based immunotherapeutic vaccine for treatment of cancer. This vaccine consists of
autologous mononuclear cells stimulated and loaded with an immunostimulatory fusion
protein containing the prostate tumor antigen prostate acid posphatase. The choice of
antigen might be key for the efficiency of cell-based immunotherapy. Depending on the
treatment strategy, target antigens should be immunogenic, abundantly expressed by
tumor cells, and preferably functionally important for the tumor to prevent loss of anti-
gen expression. Autoimmune responses have been reported against several antigens
expressed in the prostate, indicating that PCa is a suitable target for immunotherapy. In
this review, we will discuss PCa antigens that exhibit immunogenic features and/or have
been targeted in immunotherapeutic settings with promising results, and we highlight the
hurdles and opportunities for cancer immunotherapy.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer among men in the United States and is the
second leading cause of death from cancer in men (1). In Europe,
PCa is also the cancer type with the highest incidence in men
apart from skin cancer, while it is the third most common
type of cancer after lung cancer and colorectal cancer (2). PCa
is usually diagnosed in men above 65 years of age. Depending
on the severity of the disease, current treatment options for
PCa consist of active surveillance, prostatectomy, radiation ther-
apy, hormonal therapy, or chemotherapy. Up to one-third of
patients with a localized tumor eventually fails on local ther-
apy and progress to advanced-stage or metastatic PCa within
10 years. For advanced PCa, androgen deprivation therapy is
the standard of care. Although the majority of patients ini-
tially respond, most tumors become resistant to primary hor-
monal therapy within 14–30 months (3). For men with metastatic
castration-resistant prostate cancer (mCRPC), the median sur-
vival in phase III studies range from 15 to 19 months. For several
years, the chemotherapeutic drug docetaxel was the only treat-
ment option for mCRPC, resulting in a median overall survival
benefit of 2–3 months compared with the previous treatment
regimes mitoxantrone and prednisone (4–6). However, new agents
targeting the androgen signaling pathway, immunotherapeutic
options, radium-223 treatment, and the new chemotherapeu-
tic treatment modality taxane cabazitaxel are emerging therapies
with the ability to improve both the survival and the quality
of life.
In 2010, the first cellular immunotherapy was approved as
a treatment for mCRPC by the US Food and Drug Adminis-
tration (FDA). More recently, cancer immunotherapy hit a new
peak, Science Magazine elected cancer immunotherapy the break-
through of 2013 (7). Especially, modulation of T-cell checkpoints
via immune checkpoint inhibiting [anti-cytotoxic T lymphocyte
antigen-4 (CTLA-4) monoclonal antibodies and anti-programed
death (ligand) 1 (PD-(L)1] monoclonal antibodies has been suc-
cessful. Instead of tacking of the brake of the immune system, as is
the case with checkpoint inhibitors, another challenge is out there:
enhancement of immune responses to tumor-specific antigens.
In this review, we discuss tumor antigens expressed by PCa, how
they can be used to combat PCa via immunotherapy, and which
hurdles need to be addressed and overcome. Other new treatment
modalities are beyond the scope of this study.
INFLAMMATORY RESPONSES IN THE PROSTATE
Inflammation is an innate response to harmful stimuli, such
as infections, tissue damage, or tissue malfunction (8, 9). The
main goal with the inflammatory process is to clear the poten-
tial threat and restore tissue homeostasis. This normally occurs
in two phases – the recognition and elimination phase and
the resolution and repair phase (8, 10). If the acute response
fails in eliminating the inflammatory agents, the inflammation
shifts toward a chronic state. Instead of initiating the resolution
phase, additional macrophages and lymphocytes are recruited and,
depending on the inflammatory inducer, act to remodel the local
microenvironment to adapt to an altered tissue homeostasis.
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Cancer has been described as a wound that refuses to heal (11),
and today many cancers have been tightly correlated with pre-
ceding inflammatory responses (12, 13). Several lines of evidence
support the theory that inflammation also precedes PCa (9). Pro-
liferative inflammatory atrophy lesions are areas in the prostate
with an increased infiltration of inflammatory cells. These regions
can merge with prostatic intraepithelial neoplasia, which is consid-
ered to be a risk factor for the development of PCa (14, 15). Also, a
correlation with regular intake of non-steroidal anti-inflammatory
drugs and reduced PCa risk has been observed (16–18).
AUTOIMMUNITY AND PCa
Inflammatory response inducers in prostate vary from infections
to life style factors, such as diet or smoking (19). Symptomatic pro-
statitis caused by bacterial infection has been correlated with an
increased risk of PCa development (20, 21). However, the causing
agents of the majority of symptomatic and asymptomatic pro-
statitis are not well characterized and are probably multifaceted
events (22).
Several studies have reported autoimmune responses against
both seminal proteins (23, 24) and prostate antigens causing pro-
statitis to become chronic (25–27). These finding are additionally
verified in animal models, where a cytotoxic cellular response
seems to be driving the autoimmune reaction (28). Androgen
ablation in patients with PCa is shown to induce high levels of
T-cell infiltration into both benign and cancerous prostate sites,
indicating that autoimmune responses against prostate antigens
might be hormonally regulated (29).
ANTIGEN-BASED CANCER IMMUNOTHERAPY
The increased knowledge of how specific immune responses are
evoked and the development of tools to manipulate the immune
system have enabled implementation of novel immune-based can-
cer therapies. The rationale of these immunotherapies is to induce
anti-tumor immune responses, decrease tumor-load, and change
the course of the disease. Recognition of target antigens by the
immune system is crucial. Several types of immunotherapeu-
tics have been developed, such as peptide vaccines, DNA/RNA
vaccines, cell-based vaccines, and T-cell modulators. Although
improving overall survival is the primary endpoint of most clinical
studies, a better understanding of induced T-cell responses, boost-
ing pre-existing immune responses, and the effect of the tumor
microenvironment on the T cells is needed to further improve
PCa immunotherapy.
Tumor-associated antigens in PCa can be proteins that are
present on prostate cells and on their malignant counter-
parts. Examples are prostate-specific antigen (PSA), prostate-
specific membrane antigen (PSMA), and the cancer/testis anti-
gens (CTAs). In a steady state, these antigens are not provoking
strong immune responses. Immunosuppressive mechanisms in the
prostate microenvironment, such as transforming growth factor
(TGF)-β, regulatory T cells (Tregs), or myeloid-derived suppressor
cells, will maintain prostate infiltrating lymphocytes in an inactive
state (30–32). In addition, PCa cells exploit several mechanisms
to enhance immune tolerance (33). Despite the immunosuppres-
sive microenvironment, several immunotherapeutic approaches
are able to induce or enhance tumor-specific immune responses.
In the following section, potential tumor antigens and their appli-
cation as immunotherapeutic targets will be discussed. Table 1
provides an overview of the antigens discussed and clinical results
of antigen-based immunotherapy trials.
PROSTATE CANCER ANTIGENS
PROSTATE-SPECIFIC ANTIGEN
Prostate-specific antigen is a serine protease produced primarily
in the epithelial cells lining the acini and ducts of the prostate
gland (51–53). Physiologically, PSA is present at high concentra-
tions in the seminal fluid. Its function is to cleave high molecular
weight proteins into smaller peptides, which results in liquifica-
tion of these peptides. This allows the spermatozoa to swim freely
(51). Membrane-bound PSA is expressed by most PCa cells. Upon
disruption of the prostate gland tissue by cancerous growth, PSA
is released into the circulation. There, PSA can interact with sev-
eral inflammatory cells, including fibroblasts and macrophages,
which might cause chronic inflammation (9, 54, 55). PSA serum
levels correlate with the extent of disease and are therefore a useful
tumor marker, accurately reflecting tumor status and prognostic
for clinical outcome. In case of relapse, PSA levels correlate with
tumor recurrence (51, 56). Transcription of the PSA gene is posi-
tively regulated by the androgen receptor, which can partly explain
the decline in PSA levels in response to androgen deprivation ther-
apy (52). However, high PSA levels are also observed in patients
with CRPC, due to the acquired ability of the tumor cells to main-
tain the androgen receptor function even in the androgen-ablated
environment (57).
PSA as tumor antigen
Cellular autoimmune responses against PSA have been detected in
both healthy men and patients suffering from chronic prostatitis
(26, 27, 58), suggesting that PSA has immunogenic properties. It
has been used as a target antigen in several immunotherapeutic
constructs. Hodge et al. used a vector designated TRICOM, con-
taining three co-stimulatory molecules B7-1, ICAM-1 and LFA-3,
and a PSA peptide, for T-cell stimulation (59). Using a similar
approach, Kantoff et al. studied a combination of PSA-expressing
recombinant viral vectors, where treatment with a vaccinia-based
priming vector was followed by six booster injections of a fowlpox-
based vector (PROSTVAC-VF). In the phase II, randomized con-
trolled trial in patients with mCRPC, no significant difference in
progression-free survival was detected between control group and
the vaccinated group. However, vaccinated patients had a longer
median overall survival, and a better 3-year survival (60). These
clinically meaningful results have to be confirmed in an ongoing
phase III trial (Table 2).
Other PSA-expressing vectors have been tested in phase I tri-
als in patients with PCa with rising PSA levels. Vaccinations with
vaccinia-based vectors expressing PSA resulted in stabilization of
serum PSA levels and PSA-specific T-cell responses were observed
(34). PSA-specific T cells were also detected after vaccination with
a liposome-based PSA vaccine and a dendritic cell (DC)-based
vaccine (35, 36). Treatment with a PSA encoding poxviral vec-
tor vaccine in combination with radiotherapy not only showed
PSA-specific T-cell activation, but also T-cell responses against
prostate-associated antigens not encoded by the vaccine. This is
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Table 1 | Antigens and their immunogenicity in prostate cancer.
Antigen Function Immunogenicity in PCa Human clinical trials in PCa Number of
patients with PCa
PSA Serine protease
which cleaves high
molecular weight
proteins into smaller
peptides, resulting in
the necessary
liquification for
spermatozoa to
swim freely
Stimulates CTLs in vivo Poxviral vaccine PROSTVAC-VF/PSA-TRICOM showed
a longer median overall survival when compared to
placebo (34)
82 vs. 40 controls
A phase I trial with a recombinant vaccinia virus
expressing PSA (rV-PSA) showed a stable PSA level
for at least 6 months in 14 patients (35)
33
Production of
immunosuppressive
cytokines
A study with JBT 1001, a recombinant PSA vaccine,
showed a T-cell response in eight patients (36)
10
A study reported a PSA decrease between 6 and 39%
compared to baseline in 11 of the treated patients
with PSA-loaded DCs (37)
24
PAP Protein tyrosine
phosphatase which
enhances the
mobility of sperm
Stimulates CTLs in vivo A phase I/II study reported PAP-specific T-cell
responses and an increased PSA doubling time for the
plasmid DNA accine pTVG-HP PAP when compared to
placebo (38)
22
Elevated in both prostatic
hyperplasia and PCa
Three phase III RCTs, of which two showed a
significant increase in overall survival (39, 40), and one
(41) showed a trend to increase in overall survival for
sipuleucel-T compared with placebo
341 vs. 171 placebo
(39)
82 vs. 45 placebo (40)
65 vs. 33 placebo (41)
PSMA Folate hydrolase
activity
Presented at the cell surface
and in the endothelial lumen,
the latter promotes integrin
signaling
A phase I trial reported a 50% PSA reduction in four
patients treated with 177 lutetium-labeled J591, a
radiolabeled monoclonal antibody against PMSA (42)
35
Highly overexpressed in PCa A study using an HLA-A2 restricted PMSA peptide
(LLHETDSAV) showed neither clinical nor immune
responses. The authors concluded that the used
PSMA epitope was poorly immunogenic compared
with other HLA-A2-presented peptides (43)
12
A phase II trial with DCs pulsed with PMSA peptides
showed a 50% reduction of PSA in nine patients (44)
33
PSCA Unknown,
overexpressed by
most PCas
T-cell activation and
proliferation
Two vaccination studies in humans with DCs loaded
with PSCA alone or in combination with PAP, PSMA,
and/or PSA reported that the vaccine was well
tolerated and increased both the PSA doubling time
and median overall survival of the patients (45, 46)
12 (45)
6 (46)
MUC-1 Limiting the
activation of
inflammatory
responses
T-cell proliferation A phase I/II trial with DCs loaded with MUC-1
glycopeptide and KLH showed a reduction of PSA rise
in six patients. Immune responses to KLH (6/7) and
Tn-MUC-1 (5/7) have been detected (47)
7
Radioimmunotherapy was combined with or without
low-dose paclitaxel in patients with mCRPC and
breast cancer. In two patients with mCRPC who
received m170 (MUC-1 monoclonal antibody) linked to
indium-111, a 50% decline in PSA level was shown
which lasted 2 months, and two patients described a
decrease in bone pain (48)
9
(Continued)
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Table 1 | Continued
Antigen Function Immunogenicity in PCa Human clinical trials in PCa Number of
patients with PCa
NY-ESO-1 Unknown,
expressed in a
variety of tumors
CTLs and antibody-mediated
responses
In patients with mCRPC, NY-ESO-1 peptides vaccines
were tolerable. Among nine patients, vaccinations
appeared to slow PSA doubling time, and yielded
antigen-specific T-cell responses in six patients (49)
14
Immunoactivation following an NY-ESO-1
protein-based vaccine combined with CpG showed
humoral and cellular immune responses specific for
NY-ESO-1 in 12 and 9 of the vaccinated patients,
respectively (50)
13
MAGE-A
genes
Down-regulates p53
function through
histone deacetylase
recruitment
Stimulates CTLs in vivo No human clinical trial performed in PCa
AKAP-4 Binding protein
involved in
cytoskeletal
regulation and
organization by
affecting cyclic
AMP-dependent
protein kinase-A
Stimulated CTLs in vitro No human clinical trial performed in PCa
indicative for tumor cell killing and subsequent epitope spreading
(37). Hence, PSA-targeted immunotherapy can boost conven-
tional treatment strategies to induce stronger and broader effects.
This was also shown in a recent study combining PSA-TRICOM
treatment with the T-cell checkpoint inhibitor ipilimumab, where
the majority of chemo-naive patients displayed a decline in serum
PSA levels (61).
Despite the fact that PSA-based immunotherapeutic approaches
can stimulate cytotoxic T lymphocytes (CTLs) both in vitro and
in vivo, untreated patients with PCa often fail to induce a potent
immune response against this antigen (62–64). Several factors
might contribute to this phenomenon: (i) PSA activates TGF-β,
which can suppress immune responses in the tumor microenvi-
ronment (65, 66); (ii) PSA has a negative effect on lymphocyte
proliferation and differentiation (63, 64); (iii) PSA can inhibit the
maturation, function, and survival of DCs (63, 64).
In summary, the serine protease PSA is expressed at high levels
by most PCa. Targeting PSA might not only elicit a tumor-specific
immune response, but also counteract the negative effect of PSA
on both T cells and DCs. Therefore, PSA poses as a promising
target antigen in immunotherapy, and this is underscored by the
results of phase II trials using PSA in vector-based peptide vac-
cines (60, 67). The ongoing phase III clinical trial (NCT01322490)
might provide more evidence on the clinical relevance of PSA-
TRICOM/PROSTVAC-VF vaccinations (Table 2).
PROSTATE ACID POSPHATASE
Human prostate acid posphatase (PAP) is a secreted glycoprotein
enzyme synthesized in the prostate epithelium (68). Only a few
substrates have so far been identified for PAP, including adenosine
monophosphate, phosphotyrosine, phosphocholine, phosphocre-
atine, and ErbB-2 (69, 70) Since PAP can act as a protein tyrosine
phosphatase, many other yet to be identified substrates might
be involved in the signal transduction of this protein. PAP is
secreted by the prostate gland following puberty and its expres-
sion is correlated with testosterone. It is reported to enhance the
mobility of sperm (71). Serum PAP levels are low in healthy
individuals and increased levels are associated with PCa. For
example, it is shown that PAP is aberrantly expressed in high
Gleason score PCa (72, 73). Ozu et al. showed that serum PAP
levels, like serum PSA, are significantly increased within the esca-
lating PCa disease stages. PAP is also elevated in patients with
bone metastasis, compared to those without bone metastasis
(74). Elevation of PAP is associated with significantly shortened
survival, while its decrease is correlated with responsiveness to
therapy (75–77).
PAP as tumor antigen
Due to its elevated expression in PCa, PAP has been investigated as
a possible target antigen for immunotherapeutic approaches. PAP-
specific cytotoxic T cells (CTLs) can be found in blood of healthy
donors and in patients with chronic prostatitis (26, 78, 79). In addi-
tion, patients with PCa vaccinated with DCs loaded with murine
PAP showed responses against human PAP coinciding with signif-
icant clinical anti-tumor responses (80). Specific CTLs can also be
generated by culturing with antigen presenting cells pulsed with
a PAP-derived HLA-A2 binding peptide. The obtained CTLs can
lyse peptide-loaded target cells in an antigen-specific manner, as
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Table 2 | Ongoing trials encompassing antigen-based immunotherapy.
Antigen Study design Trial identifier Immunologic endpoints
PSA Phase II trial of PROSTVAC-VF/PSA-TRICOM
with docetaxel and prednisone vs. docetaxel
and prednisone alone in patients with
mCRPC
NCT01145508 (the study is ongoing but
not recruiting new patients anymore)
Immune responses before and after
docetaxel and PSA-specific immune
responses
Primary endpoint: overall survival
Phase II trial with enzalutamide with or
without PROSTVAC-VF/PSA-TRICOM in
patients with mCRPC
NCT01867333 (ongoing and recruiting
trial, estimated completion date June
2016)
Immune response (not further specified)
Primary endpoint: to show increase in time
to progression
Phase III study of
PROSTVAC-VF/PSA-TRICOM with or without
GM-CSF in patients with mCRPC
NCT01322490 (ongoing and recruiting
trial, estimated completion date
August 2016)
No immunologic endpoints
Primary endpoint: overall survival
PAP Phase II trial of sipuleucel-T with a pTVG-HP
DNA vaccine in patients with mCRPC
NCT01706458 (ongoing and recruiting
trial, estimated completion date June
2015)
Primary endpoint: immune responses
following treatment with sipuleucel-T
Phase II trial of sipuleucel-T with concurrent
or sequential abiraterone acetate plus
prednisone in patients with mCRPC
NCT01487863 (active study, not
recruiting, estimated completion date
June 2015)
Primary endpoint: sipuleucel-T CD54
upregulation
Phase II trial of sipuleucel-T and ipilimumab
given immediately sequential vs. delayed
sequential in patients with mCRPC
NCT01804465 (active study, not
recruiting, estimated completion date
August 2015)
Primary endpoints: safety of both treatment
arms and induction of antibody responses by
sipuleucel-T, the proportion of patients on
each study arm who achieve an immune
response to PAP and/or PA2024
Phase I study of sipuleucel-T and ipilimumab
in patients with mCRPC
NCT01832870 (ongoing and recruiting
trial, estimated completion date
December 2015)
Primary endpoint: antigen-specific memory
T-cell response, antigen-specific proliferation
and antibody responses against PAP, PA2024
and PHA
Phase II trial of sipuleucel-T with or without
anti-PD-1 monoclonal antibodies and
cyclophosphamide
NCT01420965 (ongoing and recruiting
trial, estimated completion date
December 2017)
Primary endpoints: feasibility and the
immune efficacy of sipuleucel-T alone vs.
sipuleucel-T plus cyclophosphamide and
anti-PD-1 monoclonal antibodies (CT011) on
the change in specific immune response
PSMA Phase I trial of adoptive T-cell transfer
targeted to PSMA in patients with mCRPC
NCT01140373 (ongoing and recruiting
trial, estimated completion date June
2014)
No immunologic endpoints
Primary endpoint: progression-free survival
Phase II trial of PSMA antibody drug
conjugate in patients with mCRPC
NCT01695044 (ongoing and recruiting
trial, estimated completion date
January 2015)
Primary endpoints: changes in tumor
assessments, serum PSA and circulating
tumor cells
Phase II study of prodrug chemotherapy
(G-202) which is activated in situ by PSMA of
PCa cells or within cancer blood vessels of
patients with mCRPC
NCT01734681 (study is not yet open
for recruitment, estimated completion
date January 2015)
Changes in circulating tumor cells and
humoral and cell-mediated immunity to
PSMA and other known PCa antigens and to
track the persistence, accumulation, and
migration of genetically retargeted
anti-PSMA autologous T cells
Primary endpoint: safety and tolerability of
immunotherapy
(Continued)
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Table 2 | Continued
Antigen Study design Trial identifier Immunologic endpoints
Phase I trial of anti-PSMA designer T cells
after non-myeloablative conditioning in
patients with mCRPC
NCT00664196 (ongoing and recruiting
trial, estimated completion date July
2016)
Pharmacokinetics and pharmacodynamics of
the anti-PSMA designer T cells
Primary endpoint: the safety of using
modified T cells
PSCA No active or recruiting clinical trials in
patients with PCa
NY-ESO-1 Phase I trial of IMF-001 (CHP-NY-ESO-1
complex) vaccine in NY-ESO-1 expressing
malignities
NCT01234012 (active study, not
recruiting, estimated completion date
December 2013)
NY-ESO-1 specific cellular (specific CD4 and
CD8+T cells) and humoral immunity
(NY-ESO-1 antibody titer)
Primary endpoint: safety and tolerability of
the vaccine
Phase I trial of DEC-205-NY-ESO-1 fusion
protein vaccine in NY-ESO-1 expressing solid
tumors
NCT01522820 (ongoing and recruiting
trial, estimated completion date
September 2014)
NY-ESO-1 specific cellular and humoral
immunity
Primary endpoint: safety of the vaccine
MAGE-A genes No active or recruiting clinical trials in
patients with PCa
AKAP-4 No active or recruiting clinical trials in
patients with PCa
MUC-1 Phase I/II study of autologous DCs loaded
with Tn-MUC-1 peptide in patients with
CRPC
NCT00852007 (active study, not
recruiting, estimated completion date
March 2014)
Induction of CD4/CD8 responses measured
by CFSE or ICS assay and/or induction of
humoral response measured by specific
antibodies or antibody isotype switching
Primary endpoint: time to radiographic
progression
Phase I study of MUC-1 vaccine in
conjunction with poly-ICLC in patients with
recurrent or advanced PCa
NCT00374049 (active study, not
recruiting, estimated completion date
July 2014)
Primary endpoint: to evaluate the efficacy of
poly-ICLC in boosting the immunologic
response of a MUC-1 vaccine
Phase II study of L-BLP25 (Stimuvax) in
combination with androgen deprivation
therapy and radiation therapy in patients with
high-risk PCa. L-BLP25 vaccination is thought
to work via killing of MUC-1 overexpressing
cancer cells
NCT01496131 (ongoing and recruiting
trial, estimated completion date
January 2016)
Change in the ELISPOT level of
Mucin-1-specificT cells after radiation therapy
well as HLA-A2 positive prostate tumor cells in vitro (78). PAP-
specific cytolytic T-cell responses have additionally been identified
in HLA-A2 transgenic mice immunized with the PAP encoding
DNA vaccine pTVG-HP (81). Moreover, PAP peptides with the
ability to bind additional HLA-A alleles has also been described
(82, 83). Also, small clinical studies using a PAP-derived peptide
for different HLA-subclasses show promising results in patients
with PCa (84, 85). Naturally occurring PAP-specific CD4+ T cells
are only found in 7–11% of patients with PCa, but this can be
augmented by immunotherapy. Overall, these data suggest that
PAP-specific T-cell responses can be initiated, and that PAP is an
interesting candidate to use in cancer immunotherapy (81, 83, 84).
DNA-based PAP vaccine
In a PAP-based DNA vaccine, patients with CRPC received six vac-
cinations with granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) biweekly. Both humoral and cellular immune
responses were detected in 3 of the 22 patients, with an
at least threefold increase in PAP-specific IFN-gamma secret-
ing CD8+ T cells. Nine of 22 patients showed PAP-specific
CD4+ and/or CD8+ T-cell responses, but no antibody responses
were detected. Also, an increase in the PSA doubling time
was observed (86). The results of two ongoing trials will
shed light on the role of PAP-based DNA vaccines in PCa
(Table 2).
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APC-based PAP vaccine: sipuleucel-T
After three phase III randomized controlled trials, the
PAP-targeting vaccine sipuleucel-T, became the first cellular
immunotherapy ever to be approved for any malignancy by the
FDA (38, 39, 41). Sipuleucel-T is a peripheral blood mononu-
clear cell (PBMC)-based autologous vaccine. PBMCs are cocul-
tured with a fusion protein, consisting of GM-CSF and PAP,
for ex vivo activation of APCs and as tumor-associated antigen,
respectively. The proposed mechanism of sipuleucel-T is induc-
ing antigen-specific immune responses and thereby destroys PCa
cells (40).
Sipuleucel-T treatment consists of three injections at 2-week
intervals. In three phase III randomized controlled trials, an
increase in overall survival of 4 months was noticed with no differ-
ence in progression-free survival. In general, treatment was well
tolerated and only rigors and pyrexia were reported as adverse
events (38, 39, 41). The trial by Kantoff et al. showed a trend
of superior treatment outcome of sipuleucel-T in patients in the
lowest PSA-level quartile (≤22.1 ng/mL). On the contrary, in the
highest PSA-level quartile treatment with sipuleucel-T showed
only 2.8 months overall survival benefit (41). This suggests that
treatment with sipuleucel-T should be initiated directly after the
diagnosis of mCRPC, when patients have a lower tumor load,
hence less immune suppression.
To date, the OS benefit of sipuleucel-T cannot be fully explained
by the recorded immune responses. An elevated T-cell stimulation
index was observed in the sipuleucel-T treated group. Neverthe-
less, T-cell proliferation responses to the fusion protein (PA2024)
or PAP did not show a survival difference. Increased antibody levels
against PA2024 were observed in 66.2% of the sipuleucel-T treated
patients and in 2.9% of the placebo-treated patients coinciding
with a slight, although not significant, survival benefit (P = 0.08).
Increased antibody levels against PAP were noticed in 28.5% of the
sipuleucel-T treated patients and in 1.4% of the placebo-treated
patients, not correlating with survival (41). Research is currently
ongoing to define additional biomarkers that could be related to
increased overall survival.
To conclude, sipuleucel-T is the first autologous cellular
immunotherapy for the treatment of PCa. Three phase III tri-
als demonstrated crucial clinical evidence for the worthiness of
sipuleucel-T. However, although an increase in overall survival of
4 months is beneficial for the patients, it is not the breakthrough
for immunotherapy many researchers were hoping for. Cellu-
lar immunotherapy might not be a monotherapeutic alternative
for PCa. Instead, combination with standard or novel treatment
modalities might be decisive. Currently ongoing trials are focus-
ing on combination therapies with androgen deprivation ther-
apy, chemotherapy, and immune checkpoint inhibitor antibodies
(Table 2).
PROSTATE-SPECIFIC MEMBRANE ANTIGEN
Prostate-specific membrane antigen, also known as glutamate
carboxypeptidase II, is a zinc metalloenzyme with folate hydro-
lase activity that is expressed in membranes of prostate epithelial
cells (87, 88). Its function in the prostate is still unknown. Low
expression of PSMA is also found in the kidneys, salivary glands,
duodenum, and the central and peripheral nervous system.
PSMA as tumor antigen
Prostate-specific membrane antigen is highly overexpressed in
PCa and increased expression correlates with advanced disease
and metastasis (89–91). It has also been shown that PSMA is
involved in tumor angiogenesis of many solid tumors, and it is
expressed in the endothelial lumen in tumors. Normal vascular
endothelium in non-cancerous tissue is PSMA negative (92, 93).
PSMA displays several features that qualify it as a suitable tar-
get for immunotherapy. In addition to its specific expression in
the prostate, it is also a membrane-bound antigen that is pre-
sented on the cell surface, but not released into the circulation
(94). PSMA has been exploited as a possible target for PCa treat-
ment in different pre-clinical settings and in early-stage clinical
trials (42, 43, 88, 95). Wolf et al. showed that the recombinant
anti-PSMA-specific single-chain immunotoxin D7-PE40 was both
specific and highly toxic for PSMA-expressing PCa cells in vitro
and in vivo in prostate tumor-bearing mice (88). Usage of the
177lutetium radiolabeled anti-PSMA monoclonal antibody J591
induced a 50% PSA reduction in 4 of the 35 patients with mCRPC
(95). A similar PSA decrease was seen in an early clinical trial
with PSMA peptide-pulsed DCs, where 9 of 33 patients displayed
a partial clinical response (43). However, not all studies target-
ing PSMA have showed encouraging results. The PMSA-derived
HLA-A2-restricted peptide (LLHETDSAV) appeared to be poorly
immunogenic compared with other HLA-A2-restricted peptides,
both in vitro as well as in patients with PCa (42). This underscores
the importance of pre-clinical studies before clinical testing.
In summary, based on the highly specific expression pattern of
PSMA in patients with PCa, PSMA poses as a suitable target for
immunotherapy. However, early clinical trials have shown varying
results. Further research concerning PSMA-based immunother-
apy is warranted. Table 2 shows several ongoing clinical studies
targeting PSMA as a tumor antigen.
PROSTATE STEM-CELL ANTIGEN
Prostate stem-cell antigen (PSCA) is a glycosylphosphatidylinosi-
tol (GPI)-anchored protein expressed on the cell surface of both
basal and luminal cells in the normal prostate,but overexpressed by
PCa cells (44, 96). It is shown that PSCA, like other GPI-anchored
proteins, is involved in the survival of stem cells, in T-cell activation
and proliferation, and in cytokine and growth factor responses
(97, 98). Furthermore, several studies have connected the Ly-6
family of PSCA-like GPI-anchored proteins to tumor growth and
metastazation (99–102).
PSCA as tumor antigen
Its distinct expression pattern and possible function in tumor-
progression makes PSCA an interesting target for immunotherapy.
It has already been exploited in several studies, with promising
results (45, 103–105). Anti-PSCA monoclonal antibodies have
been reported to inhibit tumor growth and prolong the survival
of mice bearing human PCa xenografts (46, 106). Additionally,
a chaperone complex vaccine made of PSCA and the heat-shock
protein GRP170 was shown to enhance T-cell-mediated immune
responses, inhibit tumor growth, and prolong the life span of PCa
tumor-bearing mice (107). Two DC vaccination studies have been
performed in humans (45, 105). In the study by Thomas-Kaskel
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et al., patients with mCRPC were treated with DCs loaded with
PSCA and PSA peptides. Endpoints were safety and induction of
antigen-specific immunity. The vaccine was well tolerated in all
patients, and 6 of 12 patients showed stable disease after four vac-
cinations. One patient had a complete response. Interestingly, this
patient displayed an increase in serum PSA levels. Positive delayed-
type hypersensitivity skin reactions were seen in four patients
after four vaccinations. A positive delayed-type hypersensitivity
test was associated with increased overall survival. HLA tetramer
analysis detected high frequencies of peptide-specific T cells in one
patient, who had an overall survival of 27 months (105). In another
study, vaccinations were performed in three patients with mCRPC
using multi-epitope (PSCA, PSMA, PAP, and PSA) pulsed DCs.
The treatment was well tolerated, and significant CTLs responses
against all PSAs were observed. In addition, DC vaccination was
associated with an increase in PSA doubling time (45).
To conclude, PSCA has been used as a target for antigen-based
immunotherapy in several clinical studies due to its role in tumor
growth and metastases. Unfortunately, the study results were less
impressive than expected. This might be the reason that to date
there is no ongoing clinical trial with PSCA registered.
MUCIN-1
The mucin family members include proteins that enclose tandem
repeat structures with a high proportion of prolines, threonines,
and serines. The family consists of secreted and transmembrane
forms, designated Mucin-1 (MUC-1) to MUC-21 (108). MUC-
1 is a large cell surface glycoprotein found on the apical surface
of most glandular and ductal epithelial cells, such as the lungs,
intestines, and the prostate (109). In chronic inflammation, MUC-
1 expression is induced by inflammatory cytokines like TNF-α,
IFNγ, and IL-6. Overexpression contributes to oncogenesis by
activation of growth and survival pathways (Wnt-β-catenin and
nuclear factor-κB pathways), promoting receptor tyrosine kinase
signaling and downregulation of stress-induced death pathways
(108). MUC-1 overexpression is associated with colon, breast,
lung, prostate, and pancreatic cancer. Moreover, it is associated
with tumor-progression and correlated with advanced disease
(110–112). MUC-1 has also been shown to have immunosuppres-
sive effects in mice, and secreted MUC-1 has been shown to block
T-cell activation (113, 114). Moreover, human monocyte-derived
DCs cultured in vitro with MUC-1 peptide displayed a decreased
expression of both co-stimulatory molecules and antigen pre-
senting molecules upon activation (115). Similarly, depletion of
soluble MUC-1 in tumor cell line supernatants abolished the anti-
proliferative effect of these supernatants on T cells, and MUC-1 has
therefore been identified as a target in PCa (116). The inhibitory
effect of MUC-1 has also been demonstrated in vivo, when syn-
thetic MUC-1 decreased the immune response in patients vac-
cinated with an MUC-1 containing polyvalent peptide vaccine
(117). In a recent phase I/II trial, an autologous DC vaccine loaded
with an MUC-1 glycoproteine and KLH in patients with CRPC
was studied. Patients received three injections biweekly followed
by booster vaccinations at 6 and 12 months. The rate of PSA rise
decreased in six of seven patients. The PSA doubling time increased
from a median of 2.9 months prior to vaccination to 7.5 months
during vaccination (118). Richman et al. also showed clinical
benefit for some patients with mCRPC treated with the combi-
nation of radioimmunotherapy with an anti-MUC-1 monoclonal
antibody and paclitaxel (47) (Table 1).
Taken together, MUC-1 is important in tumor-progression and
therefore a very interesting tumor-associated antigen. Several tri-
als focusing on MUC-1 as a target for cancer immunotherapy in
PCa are ongoing (Table 2).
CANCER/TESTIS ANTIGENS
Cancer/testis antigens are normally only expressed in gametogenic
tissue. However, this group of proteins is aberrantly expressed
in several types of cancers, including PCa (48). CTAs have been
shown to contribute to tumor formation and progression (119,
120). The CTAs NY-ESO-1, the MAGE family, and A-kinase
Anchor Proteins (AKAP)-4 will be discussed here.
NY-ESO-1 is found to be expressed in a variety of malignan-
cies. It is not expressed in normal adult tissue, with the exception
of the testis. The expression of NY-ESO-1 is associated with level
of disease, and higher NY-ESO mRNA and protein expression are
observed in metastatic and advanced PCa, as compared to local-
ized tumors (120–124). The function of NY-ESO-1 is unknown,
but it is speculated to play a role in meiosis or in the assembly of the
organelles that develops over the anterior half of the head in the
spermatozoa (125, 126). The NY-ESO-1 is a promising candidate
because of its tumor-restricted expression and the identification as
one of the most immunogenic CTAs, eliciting spontaneous cyto-
toxic and antibody-mediated immune responses in patients with
NY-ESO-1 + tumors (127–129). Humoral responses against NY-
ESO-1 have been evoked by non-specific immune activation in
patients with mCRPC treated with a combination of checkpoint
inhibitor ipilimumab and GM-CSF, underscoring its immuno-
genicity (130). NY-ESO-1 has been used as target antigen in several
clinical studies. Both MHC class I and II restricted T-cell epitopes
specific for NY-ESO-1 are identified (131). MHC class I and/or II
restricted NY-ESO-1 peptides were compared in a peptide-based
vaccine trial in patients with mCRPC. The vaccine increased the
PSA doubling time and yielded antigen-specific T-cell responses in
all patients treated. The strongest results were seen in chemo-naive
patients, most likely due to a lower tumor burden, thus less tumor-
induced immune suppression (132). The immunogenic features
of NY-ESO-1 are further supported by a study using a protein-
based vaccine with CpG as an adjuvant. This vaccine was able
to prime antigen-specific B-cell responses and induced NY-ESO-
1 specific, tumor-reactive CTLs in patients with metastatic PCa,
independently of autologous NY-ESO-1 expression (49). Vacci-
nation against a tumor-specific protein without it being present,
repositions this clinical vaccination protocol toward a preventive
setting.
Second, the MAGE CTA subfamily is also expressed in
PCa. Upregulation of these CTAs is found in CRPC and is
associated with resistance to chemotherapeutic agents (50).
MAGE-A2 downregulates p53 transactivation function through
histone deacetylase recruitment, a possible explanation how
MAGE-A2 expression leads to resistance to chemotherapy (50).
Indeed, silencing of MAGE-A2 increased sensitivity to doc-
etaxel chemotherapy in PCa tumor cells (120). Expression of
MAGE-C2/CT10, another member of the MAGE-A subfamily, is
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correlated with the degree of PCa malignancy. It is an indication
of higher risk for biochemical recurrence after radical prostatec-
tomy and represents a potential target for immunotherapy (133).
Members of the MAGE-A subfamily and NY-ESO-1 are often
co-expressed in prostate malignancies.
Third, the CTA AKAP are a family of scaffolding proteins
capable of controlling intracellular signals. AKAP is involved in
cytoskeletal regulation and organization by affecting cyclic AMP-
dependent protein kinase-A (134). In the prostate epithelium,
the anchor proteins synthesize and secrete calcitonin. It has been
shown that the calcitonin secretion from malignant prostates is
several-fold higher than from benign prostates (135). The calci-
tonin receptor is expressed in malignant PCa, and its activation
stimulates growth of PCa cells via activation of cyclic AMP as
well as protein kinase C (136, 137). These mechanisms suggest a
marked increase in the invasiveness of PCa cells (138). Modulation
of protein kinase-A activation possibly interferes with the growth,
tumor genicity, and metastatic potential of advanced tumors.
First, AKAP-4 has been showed to be an immunogenic CTA in
patients with multiple myeloma (139). Later, Chiriva-Internati
et al. showed cytoplasmic and surface expression of AKAP-4 in the
LnCAP PCa cell line. AKAP-4 expression in the prostate epithe-
lial cells was shown in 13 of 15 patients with PCa, but not in
healthy subjects. Cytotoxicity assays showed that AKAP-4-loaded
DC-stimulated T cells were capable of killing autologous PCa cells
in vitro. Neither killing of AKAP-4 negative PCa cells nor nor-
mal prostate epithelial cells was observed. This underscores the
antigen specificity of the response and prevention of autoimmune
reactions (140). This makes AKAP-4 a very interesting target for
PCa anti-tumor vaccination.
To conclude, several CTAs, especially NY-ESO-1, the MAGE-
A subfamily, and AKAP-4, could serve as therapeutic targets in
the fight against PCa (120, 122, 140). Especially NY-ESO-1 is of
major relevance in PCa and a target in different ongoing trials (see
Table 2). Due to the tumor-restricted expression of CTAs, these
antigens can also be used in an adjuvant or a preventive setting
hindering the recurrence of CTA-positive tumors (49).
MIXTURE OF TUMOR-ASSOCIATED ANTIGENS
To date, many investigators underscore the importance of a per-
sonalized approach by selecting patient-specific mutations as tar-
get antigens for immunotherapy. The group of Noguchi took a
first step in a personalized direction. They performed two phase
II studies with a personalized peptide vaccine (PPV). The vaccine
consisted of four peptides based on each patient’s immunoreactiv-
ity profile. Peptides of a variety of tumor-associated antigens were
tested, including PSA, PAP, PSMA, multidrug resistance protein,
and a choice of different epithelial tumor antigens. The pep-
tides included in the vaccine were selected on their capacity to
induce CTL responses. In the first phase II trial, patients with
CRPC were randomized to PPV combined with chemotherapy
or chemotherapy only (141). Antibody responses were seen in
64% of the patients and cytotoxic T-cells responses in 72% of the
patients. An increase in progression-free survival was observed in
the PPV/chemotherapy group as compared with the patients who
only received chemotherapy. However, immune responses did not
correlate with clinical outcome in patients treated with PPV and
chemotherapy. Interestingly, the authors found that lower levels
of IL-6 before PPV vaccination were favorable for overall survival.
IL-6 have been associated with more aggressive cancer progression
and decreased survival in PCa (142). In this perspective, IL-6 may
be seen as an indicator of prognosis and a predictor of therapy
effectiveness. It is also hypothesized that inhibiting IL-6 signaling
may be beneficial in patients enduring other immunotherapeutic
treatment.
The results of the PPV vaccinations are promising. A ran-
domized trial with an appropriate control group before and after
chemotherapeutic treatment is needed to fully identify a clini-
cal benefit of PPV treatment. Currently, a vaccine consisting of
20 peptides is applied to patients with CRPC in an exploratory,
randomized, open-label study (UMIN000008209, Table 2).
PROSTATE CANCER CELL LINES
GVAX
GVAX is an allogeneic, cell-based immunotherapy consisting of
the PCa cell lines LNCaP and PC-3. These cell lines are genetically
modified with a recombinant GM-CSF adeno-based viral vector
and irradiated before administration. Clinical results in patients
with PCa are indicative for a favorable clinical outcome with no
toxicities (143, 144). These results have led to phase III trials, using
the most promising high-dose GVAX protocol. Unfortunately, due
to an even increased mortality in the GVAX-treated group, and
disappointing interim results the trials were abrogated (145, 146).
van den Eertwegh et al. combined the immune checkpoint
inhibitor ipilimumab (anti-CTLA-4) with GVAX (147). More than
50% decline in PSA level was seen in 25% of the patients. All the
responding patients got 3.0 or 5.0 mg/kg ipilimumab. There was
dose-limiting toxicity in the 5.0 mg/kg group of patients, while
the lower ipilimumab regimens were well tolerated. Markedly, all
patients with immune-related adverse events showed a decrease
in PSA levels. A small number of patients additionally displayed
an anti-PSMA antibody response. These patients had a signifi-
cant increase in median overall survival (46.5 months compared
to 20.6 months for patients without this humoral response). T-cell
monitoring studies were performed in 28 patients receiving the
combination therapy of GVAX and ipilimumab. Compared with
the control group, an increase in absolute lymphocyte counts and
enhanced CD4+ and CD8+ T-cell differentiation was observed.
These immune responses were associated with a significantly pro-
longed overall survival. In addition, an OS benefit was also seen in
case of high pre-treatment levels of CD4+, CTLA-4+, CD4+/PD-
1+, or non-naïve CD8+ T cells. Low pre-treatment frequencies of
differentiated CD4+ or regulatory T cells resulted in a prolonged
OS (148). This reveals perspectives for future biomarker research.
mRNA-TRANSFECTED DCs
An alternative approach for PCa cell lines is the use of PCa cell
line-derived RNA or tumor antigen encoding mRNA. Kyte et al.
transfected monocyte-derived DCs with mRNA derived from the
PCa cell lines LnCAP, DU-145, and PC-3. Although the gener-
ation of mRNA-transfected DC is challenging, DC vaccination
appeared feasible and safe (149, 150). Furthermore, PSA-specific
T-cell responses were detected in 12 of 19 patients with PCa who
underwent mRNA-DC vaccination (149). To date, patients are
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recruited in a phase I/II trial (NCT01197625, Table 2), study-
ing the mRNA-transfected DCs in curative resected patients with
PCa. More studies are needed to properly determine the strength
of mRNA-transfected DCs. The usage of this immunotherapeu-
tic modality within combination therapies might be of greater
significance.
DISCUSSION
In this review, we provided overview of PCa tumor-associated
antigens and how they are used to target PCa via immunother-
apy (Table 1). PSMA and PSCA are normally expressed in the
prostate gland but upregulated during cancer development and
they may play a role in tumor progression (44, 89, 96, 151).
Increased serum levels of secreted tumor antigens, such as PSA
and PAP, can be used as biomarkers for disease and disease pro-
gression (51, 73, 74). More general tumor antigens, like MUC-1,
AKAP-4, and NY-ESO-1, can also be found in PCa and might be
candidates for immunotherapeutic interventions (111, 123, 140).
MUC-1 is expressed in normal tissue and upregulated on sev-
eral tumors, where it can exert immunosuppressive effects and
attain tumor growth (110). Hence, targeting MUC-1 could have a
dual role – directing the immune response toward the tumor and
reducing immune suppression. This might also be valid for other
immunosuppressive antigens, such as the MAGE-A subfamily or
PSA (54, 120). On the other hand, the NY-ESO-1 antigen is often
immunogenic per se, and pre-existing immune responses directed
against this antigen are common in treatment-naive patients (128).
Pre-existing CTL responses against PSA and PAP in healthy indi-
viduals and patients with chronic prostatitis also support the
definition of PCa as an immunogenic tumor (26, 27), where toler-
ance against self-antigens can be broken and the immune system
can be harnessed against the tumors.
Today, the only registered product for antigen-targeted
immunotherapy in PCa is sipuleucel-T (38, 39, 41). Although the
significance of this intervention received criticism, sipuleucel-T
proves an important point: autologous cellular immunotherapy
is feasible and can indeed be developed as an approved treat-
ment modality. To date, no convincing mechanism of action has
been elucidated for sipuleucel-T. Increased immune responses
were observed but no correlation with clinical outcome could be
established. Clinical studies aiming at identifying immunological
responses and thereby hopefully providing an in-depth under-
standing of the mode of action of sipulecuel-T are ongoing. Unrav-
eling the mechanism might be beneficial for further development
of sipuleucel-T and other immunotherapeutic approaches.
Effective immune responses induced by immunotherapeutic
treatments are still not common, and probably vary depending
on tumor type, somatic differences between tumor cells, and the
tumor microenvironment (66). Several recent trials have shown
promising results in both clinical and immunological responses.
Constructs targeting the NY-ESO-1 antigen has led to signifi-
cant immunological responses, which makes NY-ESO-1 an inter-
esting antigen to target immunotherapeutic strategies in future
(49, 132). Immunological responses are also induced by sev-
eral PSA-targeting vaccines, supporting the usage of PSA as an
immunogenic tumor antigen (34–36).
Insight in the localization of the tumor antigen (on/in cells,
normal cells vs. tumor cells, in organs) and the specificity of
the antigen facilitates a precise selection of target antigens with
the intention of optimizing the translation of immunotherapeu-
tic treatments to the clinic. However, despite significant T-cell
responses, tumor progression is seen most frequently in patients
treated with cancer immunotherapy. This is due to the com-
plexity of human beings and the complexity of tumors and
metastases (152). The complexity of cancer is also described by
Fox et al. (153). This report of the collaborating immunother-
apy organizations, known as the Society for Immunotherapy of
Cancer (SITC), contains the identification of nine hurdles in
cancer immunotherapy that significantly delays clinical transla-
tion of promising cancer immunotherapeutics. We here discuss
the hurdles relevant for this review, for a complete overview, we
refer to the original article (153). The first hurdle to overcome
is the complexity of cancer, tumor heterogeneity, and immune
escape. The immune signature of the tumor, distinguished by
genetic or histological evaluation, can predict responders to can-
cer immunotherapy (154, 155). The second relevant SITC hurdle
for this review is the lack of definitive biomarkers for the assess-
ment of clinical efficacy of cancer immunotherapies. Biomarkers
to distinguish between patients responsive to initial treatment,
patients displaying immune inhibitory features, and patients with
non-immunogenic tumors, are needed. Pre-existing anti-tumor
responses or the expression of inhibitory markers are examples
of suggested biomarkers that could be used to predict treatment
outcome and individualize the treatment regime.
A correlation of immune parameters with clinical outcome after
immunotherapy is not established in patients with PCa. This can
be attributed to (i) a limited number of patients per immunother-
apeutic approach; (ii) a variation in clinical features of patients
with PCa before treatment; and (iii) the difference in clinical
signs of tumor control between conventional toxic treatments and
immunotherapeutic treatments. This last argument is also one
of the hurdles identified by the SITC. Effective immunotherapy
does not always display initial shrinkage of the tumor, but rather
a pattern of tumor growth and progression followed by shrink-
age when the tumor is recognized and destroyed by the immune
system (156–158). This paradox has been illustrated by the neg-
ative outcomes on progression-free survival or PSA responses in
the sipuleucel-T trials and PSA-TRICOM trial. Tumor swelling,
increased release of PSA due to elevated tumor cell death, and ini-
tial detrimental symptoms might be associated with a favorable
clinical outcome rather than with progressive disease, as stated
in the WHO and Response Evaluation Criteria In Solid Tumors
(RECIST) criteria (156, 157, 159). Although clinically responding
patients might have been missed, some patients do not respond,
neither clinically nor immunologically. Lack of immunogenicity of
the antigens used might be an explanation, but a major factor is the
immunosuppressive networks within cancer patients. Infiltrating
lymphocytes can be regulated by a number of inhibitory pathways
within the tumor and thereby shift the direction of the ongoing
immune response toward a more tolerogenic one. Other patients
might have “silent” tumors that do not display an inflammatory
phenotype and hence do not attract lymphocyte infiltration (66).
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Novel monoclonal antibodies targeted against inhibitory recep-
tors on T cells (anti-CTLA-4 and anti-PD-1) are able to pro-
long their effector functions and prevent immune inhibition.
These treatment strategies are tested in combination with other
immunotherapeutic approaches and showed promising results in
a subset of patients (61, 147, 160). There are still ongoing combi-
nation therapy studies with ipilimumab and sipuleucel-T which
will hopefully overcome the immunosuppressive signals provided
by immune evading tumors (NCT01804465 and NCT 01832870).
Although antigen-based immunotherapy itself seldom gives rise to
severe autoimmune reactions, the combination with an immune
checkpoint inhibitor likely will enhance the risk of immune-
related adverse events, as recently shown in melanoma patients
treated with ipilimumab (161–163).
FUTURE CHALLENGES AND OPPORTUNITIES
Until recently, patients with mCRPC had limited treatment
options and a poor prognosis. With new sequential hormonal
therapies, second-line chemotherapy, and new immunotherapeu-
tic strategies, a new era has started. To date, PCa is one of the few
tumor types in which immunotherapy is part of the current stan-
dard of care. Augmenting immune responses to PCa antigens is a
valid therapeutic approach, and clinical responses with minimal
toxic effects are observed.
In this review, we focused on commonly expressed tumor-
associated antigens. Recently, patient-specific epitopes are iden-
tified as highly important to improve T-cell reactivity. Targeting
these patient- and cancer-specific mutated epitopes holds promise
for even better results and possibly cure of patients. By complete
genome and transcriptome, sequencing and mass spectrometry-
mutated HLA-binding peptides, so-called neoantigens, might
be identified (164). Vaccination with individually overexpressed
tumor-specific peptides could result in a unique,personalized anti-
cancer vaccine (165–167). Recently, the first two demonstrations of
autologous cancer exome-based T-cell responses against patient-
specific neoantigens in humans were published (167, 168). This
knowledge is a major step forward for both the identification of
new diagnostic strategies by tumor exome analysis, as well as for the
development of individualized immunotherapeutic approaches.
Combination therapies harboring these patient-specific peptide
vaccinations together with immune checkpoint inhibitors are
likely to generate an even better immune control. There is no doubt
that these are very exciting times for cancer immunotherapy.
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